Statement on the Pediatric Surge From Federally Funded Pediatric Groups
NEW HAVEN, Conn. – November 9, 2022 – (Newswire.com)
Amid the wave of se…
Advertising Press Release Distribution | Reality TV | Lifestyle Magazine | Kiev Plastic Surgery
Health news
ACDIS survey, sponsored by Iodine Software, examines what defines CDI program success, how CDI leaders view their team’s value, and what aspect of their program they would eliminate.
AUSTIN, Texas – November 9, 2022 – (Newswire.com)
Leading enterprise AI software provider Iodine Software today announced a national study of clinical documentation improvement (CDI) leaders that uncovers a number of key insights about how they view their roles and define CDI program success. The survey was conducted by the Association of Clinical Documentation Integrity Specialists (ACDIS) and sponsored by Iodine Software.
CDI programs are a critical component of every healthcare system’s revenue-cycle team, where clinical resources review medical record documentation for completeness and accuracy.
Accurate and complete documentation is proven to increase earned reimbursement and reduce compliance risks for healthcare systems. If the clinical documentation is incomplete or unclear, CDI specialists query the provider prior to final claim submission to ensure accurate and complete billing, reducing costly and cumbersome issues that can arise during claims adjudication.
Given the ongoing revenue challenges presented by COVID-19 and other market forces, the study was conducted to understand how to best support CDI leaders as they manage their teams.
The 2022 ACDIS CDI Leadership Council CDI Programmatics survey, which included surveys of 222 CDI leaders, found that nearly all CDI leaders (91%) track financial impact as a measure of departmental success, followed by 68% who use severity of illness (SOI) / risk of mortality (ROM) impact, and 53% who consider the observed-to-expected mortality rate. An additional 28% think observed-to-expected patient length of stay is an important metric that demonstrates CDI program success.
Additional key findings in the study include:
Measuring the Effectiveness of CDI Programs
According to the study, the four most-popular measures that identify CDI program effectiveness are:
Most CDI Leaders Feel Valued – But Not All
Eighty-four percent (84%) of CDI leaders report that their program is valued internally by their hospital administrations; however, approximately one in 10 felt undervalued (~11%). In a recent virtual panel discussion, CDI leaders discussed why communicating the value of the CDI team is important. Additionally, these leaders indicated a need to support the CDI team by providing personal feedback to individual team members and department score cards that highlight achieved outcomes.
Optimizing Performance: CDI Leaders’ Challenges to Achieving Top Performance
Respondents to the ACDIS survey reported that the biggest barrier to their CDI team reaching peak performance is a lack of staffing resources (36%), followed by physician engagement challenges (22%) and a lack of technology resources (18%). An additional 9% felt that organization priorities are not aligned properly.
Staffing challenges have persisted in the CDI profession, as workforce shortages, budget gaps and fierce competition for talent continue to plague the industry. Physician engagement also has historically been a challenge for CDI, because stretched providers often experience significant administrative burdens that result in frustration and burnout. In recent years, physician query and AI-driven CDI tool platforms have played central roles in supporting CDI team performance to drive greater efficiency, reduce workload and drive provider engagement.
Supporting CDI to Work More Efficiently: What CDI Duties Are Most Cumbersome?
While CDI is critical to the financial health of every healthcare system, the role can include extremely tedious tasks that contribute to CDI burnout. In the ACDIS leadership survey, CDI leaders outlined what aspects of the workflow they would eliminate if they could. The number-one responsibility named varied greatly and included, in order:
To help reduce the burdens presented by these and other listed duties, many CDI leaders are implementing in-house and third-party technology solutions that better engage providers and identify a prioritized worklist of cases to review. These CDI tools also leverage new technology that automates and augments clinical human resources and are becoming increasingly important as more work is performed virtually instead of within hospital walls.
“Based on our experience working with nearly 1,000 of the top hospitals in the U.S., Iodine Software deeply understands the market forces affecting the CDI industry, so we know they are under pressure to work more efficiently and capture more earned revenue for a hospital’s bottom line,” said Iodine Software Co-founder and CEO William Chan. “This study reinforces the need for AI-backed solutions that augment the great work that CDI specialists perform every day.”
ACDIS discussed the study’s findings with participants from dozens of provider organizations in September. The full report also is available to download.
About Iodine Software
Iodine is an enterprise AI company that is championing a radical rethink of how to create value for healthcare professionals, leaders, and their organizations: automating complex clinical tasks, generating insights and empowering intelligent care. Iodine’s powerful predictive engine complements the skills and judgment of healthcare professionals by interpreting raw clinical data to generate real-time, highly focused, predictive insights that clinicians and hospital administrators can leverage to dramatically augment the management of care delivery – facilitating critical decisions, scaling clinical workforces through automation, and improving the financial position of health systems. For more information, please visit iodinesoftware.com.
PR Contact:
[email protected]
Contact Information:
Amanda Wratchford
VP of Marketing
9042522156
Press Release Service
by
Newswire.com
Chike Mocha Mint Protein Iced Coffee is back!
ABILENE, Texas – November 9, 2022 – (Newswire.com)
Many say it’s ‘the most wonderful time of the year’ and Chike Nutrition customers would have to agree. Chike Nutrition is ringing in the holidays and bringing cheer with the return of their most popular and requested seasonal flavor, Chike Mocha Mint Protein Iced Coffee. Although Chike Mocha Mint Protein Iced Coffee is available online starting Nov. 8 and in over 500 locations nationwide, it is sure to sell out quickly.
This flavor is refreshing, balanced and has a true chocolate mint flavor reminding you of that cookie in a silver sleeve. The smell of smooth mint hits first, followed by sweet chocolate notes with mint to balance, and a mid-level sweetness finish. Better yet, each serving is packed with 20 grams of non-GMO whey protein, 150mg of caffeine, and only 1 gram of sugar and 110 calories. A truly healthy option that doesn’t compromise on taste.
A verified purchaser from last year named Heidi left a 5-star review stating, “This is the best flavor I’ve ever had. I need to stock up on 10 more bags since it’s a limited edition flavor!!! I love it!!!!” Clearly, Chike Nutrition’s customers are obsessed with Chike Mocha Mint Protein Iced Coffee.
Chike Mocha Mint Protein Iced Coffee takes the place of your sugary drive-thru coffee and is the ideal breakfast booster, healthy snack, or afternoon pick me-up. If you’re looking for extra holiday cheer, adding Chike Mocha Mint protein coffee powder into recipes easily enhances delicious treats, making them a healthier choice.
“There’s an extra layer of excitement from our customers this holiday season because of the return of our Chike Mocha Mint Protein Iced Coffee. We launched this seasonal flavor for the first time last year and we couldn’t keep up with the demand. Since then, our customers have constantly made requests for it to be a permanent flavor, so much so that we made extra this year! Don’t let an iced coffee drink during the cold weather keep you from trying Chike Mocha Mint Protein Iced Coffee. Grab a bag (or two) while you can and see what all of the hype is about. You won’t be disappointed!”, said Mac Mascorro, Brand Manager of Chike Nutrition.
It’s time to put on your mittens and try this seasonal Protein Iced Coffee that is sure to bring you cheer!
###
About Chike Nutrition
Chike Nutrition is based in Abilene, Texas and proudly manufactures and produces all nine (and counting!) of their current flavors, ensuring the quality and consistency that Chike Nutrition demands in their products. You can find all of the flavors on Chike Nutrition’s website and can follow new recipes, flavor launches, and more on Instagram and Pinterest. Learn more about Chike in their overview video.
Contact Information:
Mac Mascorro
Brand Manager
Press Release Service
by
Newswire.com
Original Source:
Chike Nutrition is Adding to ‘The Most Wonderful Time of the Year’
Accomplished technology executive and innovator Dr. Niko Pagoulatos joins Spectral MD
Niko Pagoulatos
DALLAS – …
SecurePortIV In Use SecurePortIV Catheter Securement Adhesive being applied for IV securement and site protection.
MINNEAPOLIS – November 8, 2022…
NEW YORK – November 8, 2022 – (Newswire.com)
AMC Health is pleased to announce the appointment of Mr. Steve Tsamaras, a seasoned financial executive, to the position of Chief Financial Officer. This strategic appointment will strengthen AMC Health’s executive team and follows the announcement made on 19 Oct. 2022 of AMC Health’s collaboration with global leader GE Healthcare.
Mr. Tsamaras brings over 20 years of public and private company experience in a wide range of finance and business functions within various industries. He has a proven track record of, and accountability for, financial control and reporting, accounting, tax, M&A, risk and compliance, and audit, in his prior roles. He is a highly experienced finance leader having held a number of leadership roles and has helped companies maximize profitability, operational efficiencies, and capital market objectives.
“I am delighted that Steve is joining AMC Health and bringing with him his extensive financial services knowledge and experience and a proven track record of leading high-performing businesses,” said Nesim Bildirici, Chief Executive Officer of AMC Health.
Prior to joining AMC Health, Mr. Tsamaras was Chief Accounting Officer for BVI Medical, a private medical device company. Steve has held divisional finance roles with General Electric, Siemens and Liberty Mutual. Steve is an alumnus of KPMG and PricewaterhouseCoopers. He obtained his C.P.A. license in the state of Massachusetts and holds a BS in accountancy from Bentley University.
“I am very excited to be joining AMC Health at this important time in its history and look forward to working with Nesim Bildirici and the executive team in their objective of executing the delivery of the growth strategy.”
About AMC Health:
Founded in 2002, AMC Health’s Virtual Care and Remote Patient Monitoring suite of solutions leverages a superior analytics platform and a simple user interface that integrates easily into clinical workflows. AMC Health’s advanced, real-time, analytics-driven, virtual care solutions have driven outstanding and measurable outcomes to hundreds of thousands of patients across the healthcare continuum, including payers, provider systems and governmental agencies. Its FDA Class II 510(k)-cleared, clinical decision support platform is combined with end-to-end, clinical and support RPM services that enable healthcare organizations to confidently extend their services beyond the four walls of hospital and ambulatory clinic settings. AMC Health’s unparalleled corpus of peer-reviewed, published studies highlight clinical improvements for conditions including heart failure, diabetes, and hypertension, resulting in reductions in hospital admissions and substantial financial returns on investment. For more information, visit www.amchealth.com.
Contact Information:
Mari Mescolotto
Chief Marketing Officer
561-245-0511
Press Release Service
by
Newswire.com
Original Source:
New Chief Financial Officer Hire Strengthens AMC Health’s Executive Leadership Team
WASHINGTON – November 8, 2022 – (Newswire.com)
A recently published article in Experimental Biology and Medicine (Volume 247, Issue 18, September, 2022) improves our understanding of genomic transposable elements and Parkinson’s disease. The study, led by Dr. Sulev Koks, head of Genetic Epidemiology Research at Perron Institute for Neurological and Translational Science and the Centre for Molecular Medicine and Innovative Therapeutics at Murdoch University (Australia), and Dr. John Quinn, chair of Neurobiology in the department of Pharmacology and Therapeutics at the University of Liverpool (United Kingdom), describes how transposable elements were associated with Parkinson’s subtypes and impact disease trajectory.
Transposable elements make up more than 70% of the human genome, but until recently, they have been considered as ‘junk’ DNA without any meaningful function. These elements have been largely ignored in most genetic studies and could therefore contribute to the currently unknown genetic factors that influence disease development. Prior studies by Koks and colleagues have shown that these elements have a significant regulatory role in the genome. They regulate the expression of many genes, orchestrate complex genetic activation where multiple genes are needed for a complex response, and a growing body of evidence suggests that these elements have a major pathogenetic effect, with several elements shown to cause disease.
This study, led by Dr. Koks, analyzed the variation of transposable elements and their impact on different trajectories of Parkinson’s disease. They used patient data from the Parkinson’s Progression Markers Initiative, and five-year follow-up data from Parkinson’s patients who also had whole genome sequencing data available. This allowed them to develop a comprehensive genomic screen for the transposable elements in these patients. Koks et al found that transposable elements were associated with Parkinson’s subtypes and disease trajectory. Some transposable elements predicted faster progression of the disease, with very fast deterioration of motor or cognitive functions. The effect of transposable elements wasn’t unidirectional. Depending on their type and position in the genome, these elements had a negative or positive effect. Some elements were associated with a strong and clinically meaningful change in functional Parkinson’s scores. At the same time, some transposable elements were protective and associated with a slower disease progression suggesting a slowing of neuronal loss and neurodegeneration.
Dr. Koks said: “Transposable elements are part of the genome which is known as the ‘dark genome.'” He continued: “Our study showed that the dark genome may have a much more significant impact on the pathophysiology of complex disease than previously estimated. The elements inside the dark genome could enhance or slow the progression of Parkinson’s disease and therefore open up new opportunities for precision medicine.” Dr. Quinn added, “Our body of work over a decade highlights the importance of targeting these elements for therapeutic intervention in the progression of neurodegenerative diseases which is the subject of our current work not only in Parkinson’s Disease but also Motor Neurone Disease. This could include repositioning of drugs from other disease areas in which these elements are implicated in disease progression.”
Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said “This fascinating study by Koks and his colleagues demonstrates that the presence or absence of transposable elements controls the progressions trajectory of Parkinson’s Disease. It further underscores the importance of rigorous analysis of these genomic elements is essential for considering therapeutic opportunities.”
Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership visit www.sebm.org. If you are interested in publishing in the journal, please visit http://ebm.sagepub.com.
For more information, please contact [email protected].
Contact Information:
Benjamin Zimmer
Press Release Service
by
Newswire.com
Original Source:
Genomic transposable elements modify the progression of Parkinson’s disease
In partnership with Clearway Health, Signature Healthcare has opened a convenient new pharmacy location
Signature Healthcare and Clearway Health cu…